The double upgrade from Leerink, combined with strong institutional buying and upward EPS revisions, supports a bullish bias. However, the high short interest and mixed insider signals suggest waiting for confirmation above $230 before adding size.
JNJ drugs
JNJ drug pipeline →- ▲ DARZALEX 4/10 Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
- ◆ IMAAVY 4/10 Approved (first indication); NDA under FDA review for wAIHA
- ● SPRAVATO 4/10 Approved
- ▲ TREMFYA 4/10 Approved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co
- ▲ CARVYKTI 3/10 Approved (marketed); ongoing Phase 2/3 studies
- 12 more · All JNJ drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $230.79entry
- T+1 · 6mo ago −1.88%α −0.65% · $226.46
- T+5 · 6mo ago +0.34%α +1.06% · $231.58
- T+20 · 5mo ago +4.37%α +5.23% · $240.87
- T+60 · 3mo ago +13.24%α +9.92% · $261.35
Price Chart
How similar events traded
Executive Summary
Leerink Partners issued a double upgrade on May 13, 2026, moving from Market Perform to Outperform with a $265 price target, implying 18% upside from the current $224.26. The firm has a below-average 49% accuracy on 257 calls but a strong 12.7% average return, suggesting selective timing. Consensus is bullish: 20 of 32 analysts rate Buy or Strong Buy, 12 Hold, 0 Sell. The mean target is $252.42 (13% upside), with a high of $285 and low of $155. Leerink's $265 target sits above the median of $259. Momentum is positive, 1 upgrade, 0 downgrades in 30 days, and EPS revisions are net upward for the next quarter and fiscal year. Insider activity is minimal: one small $325K sell by an officer in February. Congressional trades show three small sells and one small buy, all non-material. Institutional flows are mixed: FMR added 39.7%, Norges Bank initiated a $6.9B position, but Two Sigma cut 90.5% and Renaissance exited. Short interest is elevated at 58.9% of TRF volume, a potential squeeze catalyst. Bottom line: a contrarian double upgrade from a mid-accuracy firm with strong returns, supported by upward EPS revisions and institutional buying, but high short interest and mixed insider signals warrant caution.
Impact Score
Consensus & Targets
Consensus is bullish: 6 Strong Buy, 14 Buy, 12 Hold, 0 Sell, 0 Strong Sell across 32 analysts. The majority (20 of 32) are bullish, with no bearish ratings. Leerink's upgrade aligns with the consensus direction but is more aggressive than the average view.
Current price: $224.26. Mean target: $252.42 (13% upside). Median: $259. High: $285. Low: $155. Leerink's $265 target is above the mean and median, ranking in the top quartile. Implied upside of 18% is above the consensus average, reflecting a more bullish stance.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-13 | Leerink Partners | upgrade | Outperform | $265.00 |
| 2026-04-15 | Barclays | maintain | Equal-Weight | $255.00 |
| 2026-04-15 | Stifel | maintain | Hold | $250.00 |
| 2026-04-15 | Wells Fargo | maintain | Overweight | $263.00 |
| 2026-04-10 | Morgan Stanley | maintain | Overweight | $267.00 |
| 2026-03-30 | RBC Capital | reiterate | Outperform | $255.00 |
| 2026-03-19 | Barclays | maintain | Equal-Weight | $234.00 |
| 2026-03-17 | HSBC | maintain | Buy | $280.00 |
| 2026-03-11 | Citigroup | maintain | Buy | $274.00 |
| 2026-03-05 | JP Morgan | maintain | Neutral | $250.00 |
30-day analyst activity: 1 upgrade (Leerink), 0 downgrades. EPS revisions are net positive: next quarter (+10 up, 0 down in 7 days; +10 up, 5 down in 30 days), next fiscal year (+4 up, 0 down in 7 days; +20 up, 1 down in 30 days). Current quarter estimates show slight downward pressure (+5 up, 0 down in 7 days; +6 up, 10 down in 30 days). Overall, estimates are being revised higher for the medium term.
Firm Track Record: Leerink Partners
Leerink Partners accuracy: 49% on 257 calls | avg return: 4.3%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 13 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Raymond James | 100% | 4/4 | 8.2% | top tier |
| Barclays | 100% | 4/4 | 12.4% | top tier |
| Goldman Sachs | 100% | 4/4 | 8.8% | top tier |
| UBS | 100% | 2/2 | 17.3% | top tier |
| Stifel | 100% | 2/2 | 11.2% | top tier |
| Morgan Stanley | 91% | 10/11 | 9.6% | top tier |
| B of A Securities | 89% | 8/9 | 9.3% | top tier |
| Citigroup | 83% | 5/6 | 10.3% | top tier |
| RBC Capital | 72% | 13/18 | 4.9% | top tier |
| Wells Fargo | 67% | 2/3 | 2.7% | top tier |
Leerink Partners has a 49% accuracy rate on 257 calls, below the peer average. However, its average return of 12.7% is strong, ranking above many top-tier firms like Raymond James (8.2% on 4 calls) and Barclays (12.4% on 4 calls). Best performers: UBS (100% accuracy, 17.3% avg return on 2 calls), Barclays (100%, 12.4%), Goldman Sachs (100%, 8.8%). Worst: Cantor Fitzgerald (44% accuracy, -2% avg return on 16 calls). Leerink's accuracy is low, but its return profile suggests it makes high-conviction, well-timed calls.
Earnings Estimates
Next earnings: Jul 14, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $3.02 | $2.96 to $3.11 | $25.3B | ↑10 ↓0 |
| +1y | $12.71 | $12.07 to $13.47 | $107.2B | ↑4 ↓0 |
| 0y | $11.58 | $11.47 to $11.82 | $100.9B | ↑3 ↓0 |
| 0q | $2.84 | $2.65 to $3.00 | $25.0B | ↑5 ↓0 |
Cross-Platform Signals
Insider trades: one $325K sell by officer Schmid Timothy on Feb 20, small, non-informative. Congressional: three small sells ($1K-$15K each) by Republicans, one small buy by Democrat Lloyd Doggett, negligible. Institutional: FMR added 39.7% ($3.9B), Norges Bank initiated a $6.9B position, strong bullish signals. Two Sigma cut 90.5% ($19.8M) and Renaissance exited, bearish. Short interest is 58.9% of TRF volume, elevated and potentially a squeeze catalyst. The analyst upgrade converges with institutional buying and upward EPS revisions but diverges from the small insider sell and some institutional exits. Overall, the bullish signal is supported by large institutional inflows and upward estimate momentum.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
21 reports on JNJ
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +7.96% at T+60 after the Apr 14, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $285.75 −1.38% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $285.75 +0.79% settles Feb 10
- Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $285.75 +14.94% settles Jan 8
- Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $285.75 +10.47% settles Dec 28
- Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $285.75 +5.36% settles Dec 21
- Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $285.75 +7.28% settles Dec 4
- Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 Now $285.75 +4.51% ▲ +3.70% +5.25% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $285.75 +8.91% ▲ +7.02% +9.96% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 Now $285.75 +9.14% ▲ +1.67% +4.08% vs SPY
- Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $285.75 −9.14% ▼ −1.67% −4.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers